Structure of Tucidinostat
CAS No.: 1616493-44-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Tucidinostat is an inhibitor of HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor with IC50s of 95, 160, 67 and 78 nM, espectively.
Synonyms: Chidamide; HBI-8000; CS 055
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1616493-44-7 |
Formula : | C22H19FN4O2 |
M.W : | 390.41 |
SMILES Code : | O=C(NC1=CC=C(F)C=C1N)C2=CC=C(CNC(/C=C/C3=CC=CN=C3)=O)C=C2 |
Synonyms : |
Chidamide; HBI-8000; CS 055
|
MDL No. : | MFCD28100259 |
InChI Key : | SZMJVTADHFNAIS-BJMVGYQFSA-N |
Pubchem ID : | 12136798 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
4T1 breast cancer cells | 2.5, 5, 7.5 μM | 24 hours | To assess the effect of Tucidinostat on cell proliferation, results showed significant suppression of cell proliferation | PMC9648046 |
LLC lung cancer cells | 2.5, 5, 7.5 μM | 24 hours | To assess the effect of Tucidinostat on cell proliferation, results showed significant suppression of cell proliferation | PMC9648046 |
CT26 colorectal cancer cells | 2.5, 5, 7.5 μM | 24 hours | To assess the effect of Tucidinostat on cell proliferation, results showed significant suppression of cell proliferation | PMC9648046 |
Raw 264.7 cells | 2.5, 5, 7.5 μM | 24 hours | To assess the effect of Tucidinostat on M1 polarization of macrophages, results showed increased expression of M1 markers iNOS and CD86 | PMC9648046 |
bone marrow-derived macrophages (BMDMs) | 2.5, 5, 7.5 μM | 24 hours | To assess the effect of Tucidinostat on M1 polarization of macrophages, results showed increased expression of M1 markers iNOS and CD86 | PMC9648046 |
MV411 cells | 0, 0.25, 0.5 and 1.0 μM | 48 hours | Evaluate the antiproliferative activity of Tucidinostat, results showed that the IC50 value of Tucidinostat on MV411 cells was 2.00 ±0.15 mM. | PMC10951978 |
SK-UT-1 | 1–25 µM | 48 hours | Tucidinostat inhibited the proliferation of SK-UT-1 cells in a dose-dependent manner. | PMC9735512 |
MES-SA | 1–25 µM | 48 hours | Tucidinostat inhibited the proliferation of MES-SA cells in a dose-dependent manner. | PMC9735512 |
K562 cells | 1 µM | 72 hours | To evaluate the effect of Tucidinostat on K562 cells, the results showed that Tucidinostat treatment significantly altered Dox-btn1 binding events, mainly enhancing binding events and creating new binding sites. | PMC10497411 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
BALB/c or C57 BL/6 mice | CT26 colorectal cancer model | Oral gavage | 12.5, 25, 75 mg/kg | daily, for 10 days | To assess the effect of Tucidinostat on tumor growth and immune microenvironment, results showed that 25 mg/kg dose significantly inhibited tumor growth and promoted CD8+ T cell infiltration | PMC9648046 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02718066 | Melanoma Rena... More >>l Cell Carcinoma Non-Small Cell Lung Cancer Less << | Phase 1 Phase 2 | Recruiting | January 2020 | United States, Arizona ... More >> [Site 02] Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Thai Ho United States, California [Site 11] University of California, San Diego Medical Center Recruiting La Jolla, California, United States, 92037 Contact: Lyudmila Bazhenova United States, Florida [Site 01] Hematology - Oncology Associates of the Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 34952 Contact: Heather Yeckes-Rodin [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. Recruiting Tampa, Florida, United States, 33612 Contact: Nikhil Khushalani United States, Maryland [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute Recruiting Frederick, Maryland, United States, 21702 Contact: Elhamy Eskander United States, Texas [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics Recruiting Houston, Texas, United States, 77030 Contact: Siqing Fu Less << |
NCT03574402 | Carcinoma, Non-Small-Cell Lung | Phase 2 | Not yet recruiting | December 30, 2024 | - |
NCT02697552 | Non-Hodgkin's Lymphoma | PHASE1 | COMPLETED | 2025-10-16 | Nagoya City University Hospita... More >>l, Aichi, Japan|Fukuoka University Hospital, Fukuoka, Japan|NHO Kyushu Cancer Center, Fukuoka, Japan|Kagoshima University Medical and Dental Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|NHO Kumamoto Medical Center, Kumamoto, Japan|NHO Nagasaki Medical Center, Nagasaki, Japan|National Cancer Center Hospital, Tokyo, Japan Less << |
NCT03605056 | Multiple Myeloma | Phase 2 | Not yet recruiting | July 31, 2022 | China, Shanghai ... More >> 180 Fenglin Road Active, not recruiting Shanghai, Shanghai, China, 200032 Less << |
NCT03617432 | Experimental Tumor | Phase 2 | Recruiting | September 30, 2022 | China ... More >> Beijing Cancer Hospital Recruiting Beijing, China, 100142 Contact: Jun Zhu, MD +86-10-88196596 zj@bjcancer.org Contact: Weiping Liu, MD +86-10-88196109 dreaming2217@126.com Principal Investigator: Jun Zhu, MD Less << |
NCT03602131 | Hodgkin Lymphoma ... More >> Non-hodgkin Lymphoma Less << | Phase 2 | Not yet recruiting | March 30, 2021 | - |
NCT03321890 | Peripheral T-cell Lymphoma | Phase 2 | Recruiting | December 31, 2020 | China, Guangdong ... More >> Department of Medical Oncology,Sun Yat-Sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510060 Contact: Zhiming Li, DM +86-13719189172 Lizhm@sysucc.org.cn Contact: Yu Wang, DM 86-20-87343765 Wangyu@sysucc.org.cn Less << |
NCT03151876 | Lymphoma | Phase 2 | Recruiting | December 2021 | China, Beijing ... More >> Beijing cancer hospital Not yet recruiting Beijing, Beijing, China, 100142 Contact: Yan Xie, MD Peking university third hospital Not yet recruiting Beijing, Beijing, China, 100191 Contact: Xiaoyan Ke, MD China, Chongqing The first affiliated hospital of Chongqing medical university Not yet recruiting Chongqing, Chongqing, China, 400016 Contact: Lin Liu, MD Southwest Hospital Recruiting Chongqing, Chongqing, China, 400038 Contact: Dabing Qin, MD China, Gansu General Hospital of Lanzhou military command Not yet recruiting Lanzhou, Gansu, China, 730070 Contact: Hai Bai, MD China, Henan Henan cancer hospital Not yet recruiting Zhengzhou, Henan, China, 450008 Contact: Jian Zhou, MD The first affiliated hospital of Zhengzhou university Not yet recruiting Zhengzhou, Henan, China, 450052 Contact: Xinhua Wang, MD China, Hubei Tongji Hospital Not yet recruiting Wuhan, Hubei, China, 430030 Contact: Yang Cao, MD China, Jiangsu Jiangsu province hospital Not yet recruiting Nanjing, Jiangsu, China, 210029 Contact: Wei Xu, MD China, Shanghai Rui jin hospital Shanghai jiao tong University Not yet recruiting Shanghai, Shanghai, China, 200025 Contact: Jiong Hu, MD Tong Ren Hospital Not yet recruiting Shanghai, Shanghai, China Contact: Ligen L i u, MD China, Shanxi Shan Xi Da Yi Hospital Not yet recruiting Taiyuan, Shanxi, China, 030032 Contact: Rong Gong, MD Tangdu Hospital Not yet recruiting Xi'an, Shanxi, China, 710038 Contact: Qiang Liu, MD China, Sichuan West China Hospital of Sichuan University Recruiting Chengdu, Sichuan, China, 610044 Contact: Jie Ji, MD 86-28-85422370 jieji@scu.edu.cn Affiliated Hospital of Southwest Medical University Recruiting Nanchong, Sichuan, China, 646000 Contact: Xiaoming Li, MD China, Tianjing Blood diseases hospital, Chinese academy of medica Not yet recruiting Tianjin, Tianjing, China, 300020 Contact: Lvgui Qiu, MD China, Xinjiang The first affiliated hospital of Xinjiang medical Universtiy Not yet recruiting Ürümqi, Xinjiang, China, 830054 Contact: Ming Jiang, MD China, Yunnan Kunming General Hospital of Chengdu Military Area Not yet recruiting Kunming, Yunnan, China, 650032 Contact: Sanbin Wang, MD Less << |
NCT03564704 | Leukemia Leuk... More >>emia, Acute Adult Lymphoblastic Lymphoma Leukemia, Lymphoblastic Leukemia, T Cell Adult Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma Lymphoblastic Leukemia Less << | Phase 2 Phase 3 | Recruiting | May 30, 2021 | China, Guangdong ... More >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou +862062787349 zhs1@i.smu.edu.cn Less << |
NCT03629873 | Lymphoma, Large B-Cell, Diffus... More >>e|Mantle Cell Lymphoma|Peripheral T Cell Lymphoma|Double-hit Lymphoma Less << | PHASE2 | UNKNOWN | 2021-12-31 | Hematological Department, Peop... More >>le's Hospital of Jiangsu Province, Nanjing, Jiangsu, 210029, China Less << |
NCT02879526 | Relapse/Refratory Peripheral T... More >> Cell Lymphoma Less << | Phase 2 | Recruiting | August 2019 | China, Jiangsu ... More >> HuaiAn First People's Hospital Recruiting HuaiAn, Jiangsu, China, 223300 Contact: Liang Yu, M.D., Ph.D. WuXi People's Hospital Recruiting WuXi, Jiangsu, China, 214023 Contact: Yun Zhuang, M.D. Contact: YunFeng Shen, M.D., Ph.D Less << |
NCT03023358 | Peripheral T Cell Lymphoma | Phase 3 | Not yet recruiting | March 2019 | China, Guangdong ... More >> Ru Feng Not yet recruiting Guangzhou, Guangdong, China, 510515 Contact: Ru Feng, M.D. +86 13725119762 ruth1626@hotmail.com Contact: Qi Wei, M.D. +86 13427564102 sinbad37@126.com Principal Investigator: Ru Feng, M.D. Less << |
NCT03553238 | Leukemia, Acute ... More >> Leukemia, T Cell Leukemia, Lymphoblastic Less << | Phase 2 Phase 3 | Recruiting | August 30, 2020 | China, Guangdong ... More >> Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, MD, PhD +862062787349 zhs1@i.smu.edu.cn Less << |
NCT03453255 | Chemotherapy | Phase 1 Phase 2 | Recruiting | December 31, 2020 | China ... More >> Chinese PLA General Hospital Recruiting Beijing, China, 100853 Contact: Li Yu, M.D. Ph.D. 86-010-55499003 chunhuiliyu@yahoo.com Principal Investigator: Li Yu, M.D. Ph.D. Less << |
NCT02753647 | Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | April 2019 | China, Shanghai ... More >> Shanghai Ruijin Hospital Recruiting Shanghai, Shanghai, China, 200023 Contact: Weili Zhao, MD,PhD 64370045 ext 610707 zhao.weili@yahoo.com Contact: Pengpeng Xu, MD 64370045 ext 610707 xpproc@msn.com Less << |
NCT02809573 | Peripheral T-cell Lymphoma | Phase 1 | Recruiting | December 2019 | China, Beijing ... More >> Cancer Hospital, Chinese Academy of Medical Sciences Recruiting Beijing, Beijing, China, 100000 Contact: Yuankai Shi, MD +86-10-8778-8293 syuankai@cicams.ac.cn Less << |
NCT03564470 | Leukemia Leuk... More >>emia, Acute Leukemia, Lymphoblastic Leukemia, B-cell Less << | Phase 2 Phase 3 | Recruiting | August 30, 2020 | China, Guangdong ... More >> Department of Hematology, Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Hongsheng Zhou, PhD, MD 86-20-62787349 zhs1@i.smu.edu.cn Less << |
NCT02733380 | Diffuse Large B-cell Lymphoma | Phase 2 | Recruiting | May 2020 | China, Henan ... More >> Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university Recruiting ZhengZhou, Henan, China, 450008 Contact: Yanyan Liu, M.D. +8613838176375 yyliu@zzu.edu.cn Contact: Jiuyang Zhang, Master +8615003810435 zhangjiuyang9103@163.com Principal Investigator: Yanyan Liu, M.D. Less << |
NCT01836679 | Non-small-cell Lung Cancer | Phase 2 | Completed | - | China, Beijing ... More >> Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021 Beijing Chest Hospital, Capital Medical University Beijing, Beijing, China, 101149 China, Hebei Hebei Provincial Tumor Hospital Shijiazhuang, Hebei, China, 050011 China, Jiangsu Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210009 China, Liaoning The first Hospital of China Medical University Shenyang, Liaoning, China, 110001 China, Shanghai Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University Shanghai, Shanghai, China, 200030 China, Sichuan The Second People's Hospital of Sichuan Chengdu, Sichuan, China, 82816 China, Tianjin Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China, 300060 Less << |
NCT02987244 | T Cell Non-Hodgkin's Lymphoma | Phase 1 Phase 2 | Recruiting | March 2023 | China, Beijing ... More >> Peking Union medical college hospital Recruiting Beijing, Beijing, China, 100730 Contact: Wei Zhang China, Tianjin Tianjin medical universty cancer institute & hospital Recruiting Tianjin, Tianjin, China, 300060 Less << |
NCT02886559 | AML Relapse | Phase 1 Phase 2 | Recruiting | June 2019 | China ... More >> China PLA General Hospital Recruiting Beijing, China, 100039 Contact: Li Yu, M.D Ph.D 010-66937644 chunhuiliyu@yahoo.com Principal Investigator: Li-Xin Yu Less << |
NCT03630731 | Natural Killer/T-Cell Lymphoma... More >>, Nasal and Nasal-Type Less << | Phase 2 | Recruiting | March 2020 | China, Beijing ... More >> Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Mei Dong (86)13811929322 dongmei030224@163.com Less << |
NCT03598959 | Extranodal NK/T-cell Lymphoma | Phase 2 | Not yet recruiting | December 31, 2021 | China, Sichuan ... More >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 Less << |
NCT03336632 | Leukemia, Acute ... More >> MDS Less << | Phase 2 | Not yet recruiting | March 30, 2021 | China, Sichuan ... More >> West China Hospital of Sichuan University Chengdu, Sichuan, China, 610044 West China Hospital of Sichuan University Not yet recruiting Chengdu, Sichuan, China, 610044 Contact: Jie Ji, MD 86-28-85422370 jieji@scu.edu.cn Less << |
NCT03273452 | Angioimmunoblastic T-cell Lymp... More >>homa Less << | PHASE2 | UNKNOWN | 2025-05-19 | The Affiliated Hospital of Qin... More >>gdao University, Qingdao, Shandong, 266000, China Less << |
NCT03611231 | Experimental Tumor | PHASE2 | UNKNOWN | 2022-12-30 | Beijing, Beijing, Beijing, 100... More >>000, China Less << |
NCT02753543 | Peripheral T Cell Lymphoma | PHASE2 | UNKNOWN | 2025-11-19 | Ruijin Hospital, Shanghai, Sha... More >>nghai, 200023, China Less << |
NCT03031262 | AML | Phase 1 Phase 2 | Recruiting | December 2022 | China, Tianjin ... More >> Institute of Hematology & Blood Diseases Hospital Recruiting Tianjin, Tianjin, China Contact: lijun Liu 86-22-23909237 bloodgcp@126.com Less << |
NCT03245905 | Relapsed or Refractory B-cell ... More >>Non-Hodgkin's Lymphoma (NHL) Less << | PHASE2 | UNKNOWN | 2021-12-31 | Department of Medical Oncology... More >>, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, 510060, China Less << |
NCT03201471 | Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | February 5, 2020 | China, Zhejiang ... More >> The first affiliated hospital of Zhejiang University Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Wenbin Qian, MD. PhD. (+86)13605801032 Less << |
NCT02902185 | Chronic HIV Infections | Phase 2 Phase 3 | Active, not recruiting | December 2018 | China, Guangxi ... More >> The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China China, Shaanxi Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University Xi'an, Shaanxi, China, 710038 China, Zhejiang Zhejiang University Hangzhou, Zhejiang, China Less << |
NCT03494634 | Experimental Tumor | PHASE2 | UNKNOWN | 2020-09-30 | Cancer Center of Sun Yat-Sen U... More >>niversity (CCSU), Guangzhou, Guangdong, China Less << |
NCT02482753 | Breast Cancer | Phase 3 | Active, not recruiting | March 2019 | China, Beijing ... More >> The 307th Hospital of Chinese people's Liberation Army Beijing, Beijing, China, 100021 Less << |
NCT02883374 | Adenocystic Carcinoma | PHASE2 | UNKNOWN | 2025-06-20 | Cancer Hospital, Chinese Acade... More >>my of Medical Science, Beijing, Beijing, 100021, China Less << |
NCT03268889 | Peripheral T Cell Lymphoma | UNKNOWN | 2020-09-15 | the First Affiliated Hospital ... More >>of Soochow University, Suzhou, Jiangsu, 215006, China Less << | |
NCT03410004 | Experimental | PHASE2 | UNKNOWN | 2020-09-30 | - |
NCT02856997 | Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | - | - |
NCT02815007 | Advanced EGFR-TKI-resistant No... More >>n-Small Cell Lung Cancer Less << | Phase 2 | Unknown | June 2018 | - |
NCT03105596 | B-cell Non-Hodgkin's Lymphoma | Phase 2 | Not yet recruiting | September 30, 2019 | - |
NCT03639168 | Adenoid Cystic Carcinomas ... More >> Chidamide Cisplatin Less << | Phase 2 | Recruiting | June 1, 2020 | China, Shanghai ... More >> Kai Xue Recruiting Shanghai, Shanghai, China, 200032 Contact: Kai Xue, MD 13818659448 xuekaishanghai@126.com Less << |
NCT02878278 | Lymphoma, Extranodal NK-T-Cell... More >> EBV Less << | Phase 2 | Not yet recruiting | September 2019 | - |
NCT03373019 | Chidamide Lym... More >>phoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasm by Histology Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Cyclophosphamide Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor Less << | Phase 2 | Recruiting | March 1, 2021 | China, Shanghai ... More >> Kai Xue Recruiting Shanghai, Shanghai, China, 200032 Contact: Kai Xue, MD 13818659448 xuekaishanghai@126.com China Kai Xue Recruiting Shanghai, China Contact: Kai Xue, MD 13818659448 xuekaishanghai@126.com Contact: Junning Cao, MD 13818659448 Less << |
NCT02944812 | Peripheral T Cell Lymphoma | PHASE2 | UNKNOWN | 2025-01-19 | Guangdong general hospital, Gu... More >>angzhou, Guangdong, 510080, China Less << |
NCT02513901 | Chronic HIV Infections | PHASE1|PHASE2 | COMPLETED | 2025-02-16 | Department of Infectious Disea... More >>ses, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710038, China Less << |
NCT05833724 | Relapsed or Refractory Periphe... More >>ral T-cell Lymphoma Less << | PHASE2 | RECRUITING | 2025-12-25 | Chang Gung Memorial Hospital, ... More >>Kaohsiung, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan Less << |
NCT05682755 | Leukemia, Myeloid, Acute | PHASE1|PHASE2 | RECRUITING | 2026-12-31 | West China Hospital of Sichuan... More >> University, Chengdu, Sichuan, 610044, China Less << |
NCT05890287 | HR Positive HER2 Negative Adva... More >>nced Breast Cancer Less << | RECRUITING | 2026-10-01 | 天津市肿瘤医院, Tianjin, China | |
NCT05140616 | Safety and Efficacy | PHASE1|PHASE2 | UNKNOWN | 2024-05-31 | First Affiliated Hospital,Sooc... More >>how University, Suzhou, Jiangsu, 215000, China Less << |
NCT05991973 | T Lymphoblastic Leukemia/Lymph... More >>oma Less << | PHASE2 | RECRUITING | 2025-07-27 | The First Hospital of Zhejiang... More >> Medical Colleage Zhejiang University, Hangzhou, Zhejiang, 310006, China Less << |
NCT04511351 | Lymphoma | UNKNOWN | 2020-12-30 | National Cancer Center, Cancer... More >> Hospital, Chinese Academy of Medical Scienses, Beijing, Beijing, 100021, China Less << | |
NCT02953652 | Peripheral T-Cell Lymphoma (PT... More >>CL) Less << | PHASE2 | COMPLETED | 2022-02-17 | Akita, Japan|Bunkyōku, Japan|C... More >>hūōku, Japan|Fukuoka, Japan|Isehara, Japan|Kagoshima, Japan|Kobe, Japan|Kotoku, Japan|Kumamoto, Japan|Kyoto, Japan|Maebashi, Japan|Nagoya, Japan|Okayama, Japan|Osakasayama, Japan|Sapporo, Japan|Suita, Japan|Yamagata, Japan|ōmura, Japan|Busan, Korea, Republic of|Goyang-si, Korea, Republic of|Incheon, Korea, Republic of|Seongnam-si, Korea, Republic of|Seoul, Korea, Republic of Less << |
NCT04562311 | Bladder Cancer Stage IV | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-10-30 | Cancer Center, Sun Yat-sen Uni... More >>versity, Guangzhou, Guangdong, 510060, China Less << |
NCT05747313 | Breast Cancer|Chemotherapy Eff... More >>ect Less << | PHASE1|PHASE2 | UNKNOWN | 2023-12-31 | National Cancer Center/Nationa... More >>l Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, 00, China Less << |
NCT06550336 | Peripheral T Cell Lymphoma | PHASE2 | ACTIVE_NOT_RECRUITING | 2027-12-30 | The First Bethune Hospital of ... More >>Jilin University, Changchun, Jilin, 130021, China Less << |
NCT02955589 | Adult T-Cell Lymphoma (ATL) | PHASE2 | COMPLETED | 2025-11-19 | Fukuoka, Japan|Isehara, Japan|... More >>Kagoshima, Japan|Miyagi, Japan|Miyazaki, Japan|Nagasaki, Japan|Nagoya, Japan|Oita, Japan|Okinawa, Japan|Omura, Japan|Saitama, Japan|Sapporo, Japan|Suita, Japan|Tokyo, Japan|Yufu, Japan Less << |
NCT05276713 | Breast Cancer | UNKNOWN | 2022-08-01 | The Fifth Medical Center of PL... More >>A General Hospital, Beijing, Beijing, 100071, China Less << | |
NCT04661943 | Diffuse Large B-cell Lymphoma | PHASE2 | UNKNOWN | 2022-11-30 | The First Bethune Hospital of ... More >>Jilin University, Changchun, Jilin, 130021, China Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.56mL 0.51mL 0.26mL |
12.81mL 2.56mL 1.28mL |
25.61mL 5.12mL 2.56mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|